Caterina Chillotti
Overview
Explore the profile of Caterina Chillotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
2050
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meloni A, Paribello P, Pinna M, Contu M, Ardau R, Chillotti C, et al.
Eur Neuropsychopharmacol
. 2024 Nov;
91:37-44.
PMID: 39612728
Mitochondrial dysfunctions have been reported in bipolar disorder (BD), but their role in the etiopathogenesis of BD as well as their implications in modulating response to pharmacological treatments with psychotropic...
2.
Pisanu C, Congiu D, Meloni A, Paribello P, Severino G, Ardau R, et al.
Psychiatry Res
. 2024 Sep;
342:116195.
PMID: 39299147
High rates of metabolic risk factors contribute to premature mortality in patients with severe mental disorders, but the molecular underpinnings of this association are largely unknown. We performed the first...
3.
Cocco C, Noli B, Manconi B, Contini C, Manca E, Pisanu C, et al.
Neuropsychobiology
. 2024 Sep;
83(3-4):160-169.
PMID: 39245034
Introduction: Discriminating bipolar disorder (BD) from major depressive disorder (MDD) remains a challenging clinical task. Identifying specific peripheral biosignatures that can differentiate between BD and MDD would significantly increase diagnostic...
4.
Herrera-Rivero M, Adli M, Akiyama K, Akula N, Amare A, Ardau R, et al.
Int J Bipolar Disord
. 2024 Jun;
12(1):20.
PMID: 38865039
Background: Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide risk in patients with BP....
5.
Pisanu C, Congiu D, Meloni A, Paribello P, Patrinos G, Severino G, et al.
Neuropsychopharmacology
. 2024 Feb;
49(6):1033-1041.
PMID: 38402365
Patients with severe mental disorders such as bipolar disorder (BD), schizophrenia (SCZ) and major depressive disorder (MDD) show a substantial reduction in life expectancy, increased incidence of comorbid medical conditions...
6.
Ou A, Rosenthal S, Adli M, Akiyama K, Akula N, Alda M, et al.
Transl Psychiatry
. 2024 Feb;
14(1):109.
PMID: 38395906
Lithium is the gold standard treatment for bipolar disorder (BD). However, its mechanism of action is incompletely understood, and prediction of treatment outcomes is limited. In our previous multi-omics study...
7.
Herrera-Rivero M, Adli M, Akiyama K, Akula N, Amare A, Ardau R, et al.
Res Sq
. 2023 Dec;
PMID: 38077040
Background: Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide risk in patients with BP....
8.
Kelsoe J, Ou A, Rosenthal S, Adli M, Akiyama K, Akula N, et al.
Res Sq
. 2023 Oct;
PMID: 37886563
Lithium is the gold standard treatment for bipolar disorder (BD). However, its mechanism of action is incompletely understood, and prediction of treatment outcomes is limited. In our previous multi-omics study...
9.
Herrera-Rivero M, Gutierrez-Fragoso K, Thalamuthu A, Amare A, Adli M, Akiyama K, et al.
Res Sq
. 2023 Jul;
PMID: 37461719
The link between bipolar disorder (BP) and immune dysfunction remains controversial. While epidemiological studies have long suggested an association, recent research has found only limited evidence of such a relationship....
10.
Amare A, Thalamuthu A, Schubert K, Fullerton J, Ahmed M, Hartmann S, et al.
Mol Psychiatry
. 2023 Jul;
28(12):5251-5261.
PMID: 37433967
Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental health disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not...